Office-Based Addiction Treatment: Stabilization, Maintenance, … · Naloxone rescue kit...

Office-Based Addiction Treatment:

Stabilization, Maintenance, and

Expected Struggles

Kristin Wason, MSN, APRN, CARNOffice-Based Addiction Treatment Program

Boston Medical Center

*Images used for educational purposes only. All copyrights belong to image owners*

Outline

❖ Stabilization

❖ Maintenance

❖ Monitoring Treatment Response

❖ Identifying & Addressing “Red Flags”

Outline

❖ Stabilization

❖ Maintenance

❖ Monitoring

Treatment

Response

❖ Identifying &

Addressing “Red

Flags”

Stabilization

Tools and Resources for Practice:

TIP 40: Clinical Guidelines for the

Use of Buprenorphine in the

Treatment of Opioid Addiction

http://store.samhsa.gov/product/TIP-

40-Clinical-Guidelines-for-the-Use-

of-Buprenorphine-in-the-Treatment-

of-Opioid-Addiction/SMA07-3939

❖ Goals: lowest dose that maximizes

function and minimizes side-effects

❖ Target bupe/nlx dose should be based

upon COWS scores and patient’s

progress. Maximum of 24 mg

❖ Narcotic blockade typically occurs at 16

mg bupe/nlx daily

Stabilization (1)

ASAM, 2015

SAMHSA, 2004, TIP 40

❖ Due to long half-life, most patients take

once or more commonly, twice daily

❖ Divided dosing especially helpful for

patients with chronic pain for dual

effectiveness and avoidance of narcotic

pain medications

ASAM, 2015

SAMHSA, 2004, TIP 40

Stabilization (2)

Determining the Best Dose (1)

❖ Buprenorphine side effects can mimic

symptoms of withdrawal

❖ Assess patients to determine potential

cause of symptoms

➢ Symptom timing/pattern, situational

variables, other medical causes for

symptoms

➢ Ask how the patient manages

cravings/withdrawal symptoms

➢ Adjusting timing of

medication or dividing dose

➢ Assessing correct

administration/absorption

➢ Try different bupe/nlx

formulation

Determining the Best Dose (2)

❖ Before increasing dose, may consider:

Stabilization

❖ Initially weekly visits

❖ After 4–6 weeks of stabilization,

decrease frequency

❖ Appropriate toxicology screens,

stable dose, adherence

❖ Visit frequency decreases, prescriptions

increase with stabilization

Follow up: (1)

❖ Assess medication

❖ Provide ongoing recovery education & support

❖ Evaluate mental health and follow up as needed

❖ Assess medical issues

❖ Assess: pregnancy, family planning

❖ Identify social stabilities: housing, job,

relationships

BMC OBAT Manual Follow-up Note Template

❖ Toxicology testing: urine/oral swab

❖ Breathalyzer: alcohol concerns

❖ Lab testing as indicated:

➢ Liver function tests

➢ Hepatitis C work-up

➢ HCG (pregnancy) as indicated

Follow up: (2)

ASAM (2015) Practice Guideline for the Use of Medications

in the Treatment of Addiction Involving Opioid Use.

MATx - Mobile app from SAMHSA

Psychotherapy/Counseling

❖ Building and maintaining motivation for recovery

❖ Understanding relapse triggers

❖ Developing coping and problem-solving skills

❖ Improvement in functioning including

occupational and

interpersonal skills

❖ Connection to community

Special Considerations:

❖ Persons with psychiatric

comorbidities

❖ Persons with medical

comorbidities

❖ Persons under 18 years old

❖ Persons over 60 years old

❖ Pregnant women

❖ Health care professionals

American Association for Nurse Anesthetists Peer Assistance Program

http://peerassistance.aana.com/directory.asp?State=All

Outline

❖ Stabilization

❖ Maintenance

❖ Monitoring Treatment Response

❖ Identifying & Addressing “Red Flags”

❖ Expect stability and improved social functioning

❖ Expect improvement in substance use/misuse

❖ Early outcomes improve with counseling

❖ Relapse may still occur

Maintenance

recoveryexperts.com

❖ If unable to move on to

maintenance phase of treatment

due to continued use: evaluate

progress in treatment; potential

need for dose change, increased

supports, adding structure,

alternative treatment setting

Outline

❖ Stabilization

❖ Maintenance

❖ Monitoring Treatment Response

❖ Identifying & Addressing “Red Flags”

Why Conduct Toxicology Testing?

❖ Assess treatment effectiveness

❖ Identify and reduce threats to progress

❖ Encourage self-monitoring

❖ Facilitates conversation with patient: It is a tool

❖ Intervene if relapse seems likely

Drug Testing: A White Paper of the American Society of Addiction Medicine (2013)

http://www.asam.org/docs/default-source/public-policy-statements/drug-testing-a-white-paper-by-asam.pdf

Toxicology Testing Technologies

Urine Toxicology Collection

❖ NO belongings in bathroom

❖ Supervised urine collection does not

necessarily mean observed or vice versa

❖ Check urine temperature, clarity

❖ Creatinine levels if suspect tampering

❖ If concerned: communicate with the patient,

obtain repeat sample

❖ Oral swabs: more tamper resistant, but generally

less reliable compared to urine toxicology

Confirmatory Testing of Toxicology Screens

❖ Gas Chromatography-Mass Spectrometry (GC/MS)

❖ Qualitative: Identify specific substance (parent

drug) and/or metabolite (breakdown product)

Buprenorphine = parent drug

Norbuprenorphine = metabolite

❖ Quantitative: identify level of a substance in a

solution, will give a numerical value as opposed to

simple positive or negative result

❖ With a high concentration of parent drug in

absence of metabolite - tampering should be

suspected and addressed Papoutsis et al., 2011

ASAM, 2013

Prescription Drug Monitoring Program

❖ Depending on the state: PDMP monitors

information on Schedule II through V

❖ Check PDMP before treatment, especially if

patients are having + toxicology screens

❖ PDMP will show:

➢ Prescriber

➢ Drug

➢ Dosage

➢ Frequency

➢ PharmacyDEA Diversion Control Division:

https://www.deadiversion.usdoj.gov/faq/rx_monitor.htm

Treatment Retention

Better outcomes are associated with:

❖ Medication and behavioral treatment

❖ Adequate dosing

❖ Evidence-based practices

❖ Integrated, well-coordinated treatment

❖ Strategies to deal with polysubstance

use and relapse

Outline

❖ Stabilization

❖ Maintenance

❖ Monitoring Treatment Response

❖ Identifying & Addressing “Red Flags”

Red Flags (1)

❖ Missed appointments

❖ Requests early refills of

buprenorphine or other

meds with misuse potential

❖ Decreased social

functioning

❖ Arriving impaired, or

inappropriate behavior

❖ Tampered urine screens

❖ Unable to void, or

demanding to void

immediately

❖ Calls or reports that the

patient is “selling”

medication

❖ Emergency room visits,

hospitalizations

Red Flags (2)

Diversion

National Association of Drug Diversion Investigators

❖ “Any criminal act or deviation that removes a

prescription drug from its intended path from the

manufacturer to the patient” – National

Association of Drug Diversion Investigators

❖ Includes:

➢ Theft of drugs

➢ Doctor shopping

➢ Counterfeit drugs

➢ International smuggling

➢ Selling medications

➢ Forged prescriptions

➢ Sharing medications

Medication Misuse

❖ The use of a substance for

a purpose not consistent

with legal or medical

guidelines (WHO, 2006)

❖ It has a negative impact on

health or functioning and

may take the form of drug

dependence, or be part of

a wider spectrum of

harmful behavior

World Health Organization (2006) Lexicon of Alcohol and Drug Terms Published by the World

Health Organization.

Department of Health (DH) Wired for Health Drug Use and Misuse –Definitions. 2006

.

Misuse Potential of Buprenorphine

❖ Euphoria does occur in nonopioid-

dependent individuals

❖ Misuse potential is less than full opioid

agonists

❖ Misuse by opioid-dependent individuals

is low

Yokel MA et al. ( 2011)

Alho H et al. Drug Alcohol Depend 2007)

Understanding Diversion and Misuse of

Buprenorphine

Understand Diversion:

❖ Help addicted friend

❖ Peer pressure

❖ Income

Understand Misuse:

❖ Perceived underdosing

❖ Relieve craving

❖ Relieve withdrawal

❖ Relieve other

symptoms (e.g., pain,

depression)

❖ Get high

**Slide credit: Michelle Lofwall, MD Univ of Kentucky

PCSS_MAT: Implications of Buprenorphine Diversion and Misuse.

http://pcssmat.org/event/buprenorphine-diversion-and-misuse-implications-for-policy-and-practice/

Prevent Pediatric Exposure

❖ Review program policies:

lost/stolen/destroyed medications

➢ Lockable container recommended

➢ Keep the medication in the

container it came in: childproof

❖ Never share pills

❖ Educate preventing pediatric

exposure

❖ Provide the Poison Control Center

phone number: 1-800-222-1222

This brochure available for free at:

http://massclearinghouse.ehs.state.ma.us/ALCH/SA1064kit.html

Responding to Red Flags

Response to Red Flags

Address Behavior with Patient: Quickly

❖ Have a discussion with your patient - don’t wait

until next visit

❖ Verbalize your concerns

❖ Be supportive

Establish new intensified treatment plan

❖ Patient specific—achievable in your setting

❖ Signed agreements

❖ Involve patient in the process

Revision of Treatment Plan May Include: (1)

❖ More frequent visits

❖ Shortened prescriptions

❖ Dose adjustment

❖ Loss of refills

❖ Referral to intensive outpatient program (IOP)

❖ Confirmation of counseling and team

engagement with counselor

❖ Referral to relapse prevention groups or

individual therapy

Revision of Treatment Plan May Include: (2)

❖ Psychiatric evaluation

❖ Residential treatment

❖ OTP setting for

directly observed

treatment

Referral to Higher Level of Care Includes:

❖ Detoxification/TSS/CSS

❖ Residential treatment

❖ Methadone maintenance

❖ Directly observed buprenorphine/naloxone

daily dosing in OTP

❖ Mandated treatment

❖ Dual diagnosis

Negative Buprenorphine Toxicology Screen

❖ Review medication administration

❖ Consider diversion and possible relapse

❖ Repeat testing with confirmatory test

❖ Assess and modify treatment plan

❖ Repeated neg bupe UTS = refer to higher

level of care

❖ Patients on low-dose bupe/nlx (<6 mg) may

have a bupe level that is below cutoff limits

of the test. Send for confirmation.

Positive Opioid Toxicology Screen

❖ Address ASAP and

intensify treatment plan

❖ Overdose education: safety

❖ Continued use: if risk

outweighs benefit - refer to

higher level of care

❖ May return at a later date

recoveryexperts.com

Polysubstance Use (1)

❖ Stimulants

➢ Intensify treatment plan

➢ Detox not typically an option if stimulants only

❖ CNS depressants (benzo, etoh, barbs,

promethazine, gabapentin, others…)

➢ Alcohol = breathalyzers

➢ Initially, intensify treatment plan

➢ Ongoing use encourage/refer to detox or

other higher level of care

Polysubstance Use (2)

❖ If + amphetamine or benzo:

➢ PDMP check

➢ Consider referral to psychiatry

Always Assess Risk Vs Benefit Before

Discontinuing Treatment and Provide

Appropriate Referral

Patient Refusal of Intensified Treatment

❖ Restate commitment to work with patient

and encourage to return

❖ Emphasize safety concerns

❖ Document risk/benefit discussion, why

medication discontinued, higher level of

care refused

❖ Overdose prevention education

❖ Naloxone rescue kit

Transferring to Methadone Maintenance

Communication is Key: Provider to Program

❖ With patient consent, describe treatment

history and reasons for referral

❖ Confirm last Rx and no further Rx

Support in the transfer process

❖ Behavioral screening/intake

❖ Medical intake

❖ Advocate

References

❖ Greenwald, Comer & Fiellin. (2014). Buprenorphine maintenance and

mu-opioid receptor availability in the treatment of opioid use disorder:

implications for clinical use and policy. Drug Alcohol Depend. 2014

Nov 1; 0: 1–11.

❖ ASAM. (2013). Drug Testing: A White Paper of the American Society

of Addiction Medicine http://www.asam.org/docs/default-source/public-

policy-statements/drug-testing-a-white-paper-by-asam.pdf

❖ Yokell, M., Zaller, N., Green, T., and Rich, J. (2011). Buprenorphine

and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An

International Review. Curr Drug Abuse Rev. 2011 Mar 1; 4(1): 28–41.

❖ http://www.narcan.com/

❖ Wang, Vincent, Rodrigues, Agrwal, Moore, Barhate, Abolencia,

Couter, Soares, Sheng, Taylor, and Morjana. (2007). Development

and GC-MS validation of a highly sensitive recombinant G6PDH-based

homogeneous immunoassay for the detection of buprenorphine and

norbuprenorphine in urine.Journal of Anyalytic Toxicology.

❖ Papoutsis, Nikolaou, Athanaselis, Pistos, Spilopoulou, Maravelias.

(2011). Development and validation of a highly sensitive GC/MS

method for the determination of buprenorphine and nor-

buprenorphine in blood. Journal of Pharmaceutical and Biomedical

Analysis. Volume 54, Issue 3, 20 Februrary 2011, Pages 588-591.

❖ DEA Diversion Control Division: State Prescription Drug Monitoring

Programs. https://www.deadiversion.usdoj.gov/faq/rx_monitor.htm

❖ World Health Organization (2006) Lexicon of Alcohol and Drug

Terms Published by the World Health Organization.

❖ Department of Health (DH) Wired for Health Drug Use and Misuse

–Definitions. 2006

❖ Boston Medical Center. (2016). OBAT Policy and Procedure

Manual: Policies and Procedure manual of the Office Based

Addiction Treatment Program for the Use of Buprenorphine and

Naltrexone Formulations in the Treatment of Substance Use

Disorders

❖ Harm Reduction Coalition. (2012). Overdose Prevention and Naloxone

Manual. http://harmreduction.org/issues/overdose-prevention/tools-best-

practices/manuals-best-practice/od-manual/

❖ SAMHSA. (2016) Opioid Overdose Prevention Toolkit.

http://store.samhsa.gov/product/Opioid-Overdose-Prevention-Toolkit-

Updated-2016/SMA16-4742

❖ Prescribe to Prevent, Boston University.

http://www.opioidprescribing.com/naloxone_module_1-information

❖ The Conversation: Academic rigor, journalistic flair. November 14, 2014.

http://theconversation.com/explainer-naloxone-the-antidote-to-opioid-

overdose-32481

❖ Providers Clinical Support System, For Medication Assisted Treatment.

http://pcssmat.org/

❖ SAMHSA. (2004). TIP 40: Clinical Guidelines for the Use of

Buprenorphine in the Treatment of Opioid Addiction

• TIP 40: Clinical Guidelines for the Use of

Buprenorphine in the Treatment of Opioid Addiction

• American Society of Addiction Medicine (ASAM) -

National Practice Guideline for the Use of Medications

in the Treatment of Addiction Involving Opioid Use

• Boston Medical Center - Policy and Procedure Manual

of the Office Based Addiction Treatment Program for

the Use of Buprenorphine and Naltrexone Formulations

in the Treatment of Substance Use Disorders

• SAMHSA - MATx: a Mobile App to Support Medication

Assisted Treatment of Opioid Use

Unit Resources

• American Association for Nurse Anesthetists (AANA)

Peer Assistance Program

• Drug Testing: A White Paper of the American Society of

Addiction Medicine (ASAM) 2013 (pdf)

• Drug Enforcement Administration (DEA) - Diversion

Control Division: State Prescription Drug Monitoring

Programs

• National Association of Drug Diversion Investigators

• Lexicon of Alcohol and Drug Terms Published by the

World Health Organization

• PCSS-MAT: Implications of Buprenorphine Diversion

and Misuse

• Protecting Others and Protecting Treatment: Safe

Storage of Buprenorphine (Free Brochure)

• Harm Reduction Coalition - Overdose Prevention and

Naloxone Manual (2012)

• SAMHSA - Opioid Overdose Prevention Toolkit

(2016)

• Prescribe to Prevent (Boston University)

• The Conversation - Explainer: naloxone, the antidote

to opioid overdose (November 14, 2014)

• Providers Clinical Support System for Medication

Assisted Treatment